Cargando…
Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
Dendritic cells (DCs) are antigen-presenting cells involved in T cell activation and differentiation to regulate immune responses. Lipoimmunogens can be developed as pharmaceutical lipoproteins for cancer immunotherapy to target DCs via toll-like receptor 2 (TLR2) signaling. Previously, we construct...
Autores principales: | Shen, Kuan-Yin, Liu, Hsin-Yu, Yan, Wan-Lun, Wu, Chiao-Chieh, Lee, Ming-Hui, Leng, Chih-Hsing, Liu, Shih-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225995/ https://www.ncbi.nlm.nih.gov/pubmed/32231003 http://dx.doi.org/10.3390/cancers12040810 |
Ejemplares similares
-
A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population
por: Wu, Chiao-Chieh, et al.
Publicado: (2016) -
Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment
por: Yan, Wan-Lun, et al.
Publicado: (2021) -
Delivery of Antigen to CD8(+) Dendritic Cells by Fusing Antigen With Formyl Peptide Receptor-Like 1 Inhibitor Protein Induces Antitumor Immunity
por: Chiang, Chen-Yi, et al.
Publicado: (2019) -
The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
por: Koido, Shigeo, et al.
Publicado: (2013) -
Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)